Passage Bio Stock Today
| PASG Stock | USD 1.23 0.09 7.89% |
Performance8 of 100
| Odds Of DistressOver 70
|
Passage Bio is trading at 1.23 as of the 24th of April 2024. This is a 7.89% increase since the beginning of the trading day. The stock's lowest day price was 1.1. Passage Bio has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Passage Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of February 2020 | Category Healthcare | Classification Health Care |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 61.61 M outstanding shares of which 1.32 M shares are at this time shorted by private and institutional investors with about 2.16 trading days to cover. More on Passage Bio
Moving together with Passage Stock
| 0.66 | OPT | Opthea | PairCorr |
| 0.76 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
Moving against Passage Stock
| 0.5 | EVO | Evotec SE ADR Earnings Call Today | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
Passage Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Passage Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Passage Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | William MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Passage Bio report their recommendations after researching Passage Bio's financial statements, talking to executives and customers, or listening in on Passage Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Passage Bio. The Passage consensus assessment is calculated by taking the average forecast from all of the analysts covering Passage Bio. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the analysis of Passage Bio's profitability, liquidity, and operating efficiency, Passage Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Passage Bio is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Passage Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Passage Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Passage Bio's financial leverage. It provides some insight into what part of Passage Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Passage Bio (PASG) is traded on NASDAQ Exchange in USA. It is located in One Commerce Square, Philadelphia, PA, United States, 19103 and employs 58 people. Passage Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 70.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Passage Bio's market, we take the total number of its shares issued and multiply it by Passage Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Passage Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.61 M outstanding shares of which 1.32 M shares are at this time shorted by private and institutional investors with about 2.16 trading days to cover.
Passage Bio currently holds about 239.25 M in cash with (78.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Passage Bio Probability Of Bankruptcy
Ownership AllocationPassage Bio has a total of 61.61 Million outstanding shares. Over half of Passage Bio's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Passage Bio. Please watch out for any change in the institutional holdings of Passage Bio as this could mean something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Passage Ownership Details
Passage Stock Price Odds Analysis
In reference to a normal probability distribution, the odds of Passage Bio jumping above the current price in 90 days from now is about 54.97%. The Passage Bio probability density function shows the probability of Passage Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.9981 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Passage Bio will likely underperform. Additionally, passage Bio has an alpha of 0.3114, implying that it can generate a 0.31 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Passage Bio to move above the current price in 90 days from now is about 54.97 (This Passage Bio probability density function shows the probability of Passage Stock to fall within a particular range of prices over 90 days) .
Passage Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Passage Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Passage Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Passage Bio's value.| Instituion | Recorded On | Shares | |
| Tang Capital Management Llc | 2023-09-30 | 400 K | |
| Geode Capital Management, Llc | 2023-12-31 | 332.2 K | |
| Weiss Multi-strategy Advisers Llc | 2023-12-31 | 242.9 K | |
| Two Sigma Advisers, Llc | 2023-12-31 | 210.5 K | |
| Two Sigma Investments Llc | 2023-12-31 | 201.2 K | |
| Rbf Llc | 2023-12-31 | 142.8 K | |
| State Street Corporation | 2023-12-31 | 123.9 K | |
| Fiduciary Trust Co | 2023-12-31 | 115 K | |
| Citadel Advisors Llc | 2023-09-30 | 103.5 K | |
| Orbimed Advisors, Llc | 2023-12-31 | 10.1 M | |
| Versant Venture Management Llc | 2023-12-31 | 5 M |
Passage Bio Historical Income Statement
Passage Bio Income Statement is one of the three primary financial statements used for reporting Passage's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Passage Bio revenue and expense. Passage Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Passage Bio's Depreciation And Amortization is most likely to increase significantly in the upcoming years. The Passage Bio's current Other Operating Expenses is estimated to increase to about 104.9 M, while Selling General Administrative is projected to decrease to roughly 39.5 K. View More FundamentalsPassage Stock Against Markets
Picking the right benchmark for Passage Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Passage Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Passage Bio is critical whether you are bullish or bearish towards Passage Bio at a given time. Please also check how Passage Bio's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Passage Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Passage Bio Corporate Management
Elected by the shareholders, the Passage Bio's board of directors comprises two types of representatives: Passage Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Passage. The board's role is to monitor Passage Bio's management team and ensure that shareholders' interests are well served. Passage Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Passage Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sue Browne | Senior Development | Profile | |
| Simona King | CFO Sec | Profile | |
| JD Esq | General Secretary | Profile | |
| Gregory Fuest | Vice Marketing | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Kathleen Borthwick | Principal Finance | Profile |
How to buy Passage Stock?
Before investing in Passage Bio, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Passage Bio. To buy Passage Bio stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Passage Bio. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Passage Bio stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Passage Bio stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Passage Bio stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Passage Bio, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Passage Stock please use our How to Invest in Passage Bio guide.
Already Invested in Passage Bio?
The danger of trading Passage Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Passage Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Passage Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Passage Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Passage Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.